Addressing biotech’s #1 pain point
A cost-effective service to provide credible in silico data to support pre-clinical biological asset value
Global biotech financing hit a rough patch EY stated recently : “In 2022, all types of biotech financing – venture capital investment, debt financing, IPOs, follow-on, etc. – decreased significantly. The biotech IPO market fell 93% from 2021, and an estimated 29% of public biotechs in the US and Europe had less than one year of cash on hand.”
Incubate Bio has a novel technology, ALaSCA, that rapidly generates additional biological data for promising therapeutic assets . We are announcing a new service to help biotechs reinforce the value of their pre-clinical biological assets .
ALaSCA has already been applied to successfully find oncology related targets: Dr Chris Bullock, CEO QV Bioelectronics, stated, “Using ALaSCA, we have been able to rapidly identify and collect the data we needed to cost-effectively move our research to the next stage, whilst also identifying potential targets to test in the future for synergistic therapy.” [4,5]
In just 4 - 6 weeks, we will run ALaSCA and provide you credible in silico data for fundraising, supporting your current drug discovery program as well as new indication extensions / combination therapies.
To access this service contact Dr Raminderpal Singh.